Q-omics provides the consensus-scored ZC3H11A profile across patient tissues and cancer cell-line models. ZC3H11A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZC3H11A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZC3H11A RNA expression shows 21,301 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZC3H11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H11A survival associations across molecular data types. ZC3H11A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H11A RNA expression–survival associations across cancer types. High ZC3H11A expression shows unfavorable associations in ACC, UVM, KIRP, LGG and CESC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZC3H11A RNA expression.
This table summarizes ZC3H11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H11A shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and STAD. The HNSC box plot shows higher ZC3H11A RNA expression in tumor versus normal tissue (log2 FC = +1.148, t-test p < 0.001).
This table shows molecular features associated with ZC3H11A in patient tissues and cancer cell lines. In patient samples, ZC3H11A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
